Goodwin Procter LLP (Goodwin) is a global law firm headquartered in Boston, Massachusetts, with offices in the United States, Europe, and Asia. The firm advises companies, investors, and financial institutions across sectors including life sciences, biotechnology, technology, private equity, real estate, and financial services.
For chemical and life sciences clients, Goodwin’s work spans mergers and acquisitions, venture and growth financings, capital markets transactions, joint ventures and strategic collaborations, licensing and intellectual property matters, regulatory and compliance issues, and litigation. The firm’s interdisciplinary teams support businesses at all stages—from start-ups and clinical-stage biotechs to multinational manufacturers and their investors—on corporate, transactional, and dispute matters relevant to the chemicals and broader biopharma value chain.
None yet. When a new project in the record names Goodwin as owner, partner or investor, it shows here.
Precision platform targets pathogenic autoantibodies; MER511 Phase 1 shows strong reductions in thyroid‑stimulating antibodies; deal includes up to $2.875B in cash.
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.
$38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3
Lilly acquires Orna to enhance genetic medicine and in vivo cell engineering, focusing on autoimmune diseases with circular RNA and lipid nanoparticle technology.
